Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 23.14 USD -0.34% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Bicycle Therapeutics PLC?
Write Note

Bicycle Therapeutics PLC
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bicycle Therapeutics PLC
Cash & Cash Equivalents Peer Comparison

Comparables:
CNTA
EXAI
AUTL
IMCR
GNS

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash & Cash Equivalents
$890.9m
CAGR 3-Years
51%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash & Cash Equivalents
$128m
CAGR 3-Years
161%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Cash & Cash Equivalents
ÂŁ257.6m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash & Cash Equivalents
$239.6m
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash & Cash Equivalents
ÂŁ442.6m
CAGR 3-Years
51%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash & Cash Equivalents
ÂŁ42.5m
CAGR 3-Years
-3%
CAGR 5-Years
7%
CAGR 10-Years
6%

See Also

What is Bicycle Therapeutics PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
890.9m USD

Based on the financial report for Sep 30, 2024, Bicycle Therapeutics PLC's Cash & Cash Equivalents amounts to 890.9m USD.

What is Bicycle Therapeutics PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
56%

Over the last year, the Cash & Cash Equivalents growth was 56%. The average annual Cash & Cash Equivalents growth rates for Bicycle Therapeutics PLC have been 51% over the past three years , 56% over the past five years .

Back to Top